Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?

Ansgar Felbecker
May 2010
Journal of Neurology, Neurosurgery & Psychiatry;May2010, Vol. 81 Issue 5, p572
Academic Journal
BACKGROUND: 153 mutations in the Cu/Zn superoxide dismutase (SOD1) gene have been claimed to be associated with amyotrophic lateral sclerosis (ALS) in familial and sporadic ALS in an autosomal dominant or autosomal recessive pattern with complete or reduced penetrance. The authors now report four ALS pedigrees from Finland, France, Germany and Sweden with either the D90A or E100K SOD1 mutations in some but not all affected members. After re-collecting DNA, the non-segregation of the SOD1 mutations with disease was confirmed by three independent laboratories using different PCR primers: while some of the affected patients carry SOD1 mutations, other affected family members have two wildtype/normal SOD1 genes. In addition, some unaffected members within the same families are carriers of SOD1 gene mutations. To exclude other known genetic causes, the authors ruled out mutations within the genes coding for VAPB, ANG, TDP43, FUS and DCTN1 in affected individuals in the four pedigrees. CONCLUSIONS: The authors find that the D90A and E100K SOD1 gene mutations found in some patients are not the exclusive cause of ALS in these pedigrees. Whether this is also the case for the other 151 SOD1 mutations reported in ALS pedigrees is unknown. The findings have consequences for genetic testing in clinical practice when diagnosing ALS and for genetic counselling in ALS. Some SOD1 mutations may be part of an oligo- or epigentic pattern of inheritance. Such a pattern of inheritance may model other oligo- or polygenetic traits responsible for other forms of ALS.


Related Articles

  • SHOULD A FAMILY HAVE TO FACE A UV DILEMMA? Kirk, Claire W.; Morrison, Patrick J. // Ulster Medical Journal;2009, Vol. 78 Issue 1, p65 

    With the advancement of high-throughput technologies for mutation screening, unclassified variants (UV; non-informative mutations for which the pathogenic effect is unclear) are increasingly being discovered in the BRCA1 and BRCA2 genes. There are a number of ways to try to establish the...

  • Full-Exon Pyrosequencing Screening of BRCA Germline Mutations in Mexican Women with Inherited Breast and Ovarian Cancer. Vaca-Paniagua, Felipe; Alvarez-Gomez, Rosa María; Fragoso-Ontiveros, Verónica; Vidal-Millan, Silvia; Herrera, Luis Alonso; Cantú, David; Bargallo-Rocha, Enrique; Mohar, Alejandro; López-Camarillo, César; Pérez-Plasencia, Carlos // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Hereditary breast cancer comprises 10% of all breast cancers. The most prevalent genes causing this pathology are BRCA1 and BRCA2 (breast cancer early onset 1 and 2), which also predispose to other cancers. Despite the outstanding relevance of genetic screening of BRCA deleterious variants in...

  • Nutrigenomic Testing and the Methylation Pathway. Yasko, Amy; Gordon, Garry // Townsend Letter for Doctors & Patients;Jan2006, Issue 270, p69 

    The article focuses on the significance of nutrigenomic testing in genetic evaluation in assessing risks for possible inherited health problems. Nutrigenomic testing focuses on the mutations in the methylation pathway. The functions of this pathway is important for a number of critical reactions...

  • Monogenic diabetes, renal dysplasia and hypopituitarism: a patient with a HNF1A mutation. Simms, R.J.; Sayer, J.A.; Quinton, R.; Walker, M.; Ellard, S.; Goodship, T.H.J. // QJM: An International Journal of Medicine;Oct2011, Vol. 104 Issue 10, p881 

    No abstract available.

  • Genetic testing for cancer susceptibility: the promise and the pitfalls. Lerman, Caryn; Shields, Alexandra E. // Nature Reviews Cancer;Mar2004, Vol. 4 Issue 3, p235 

    Genetic testing for hereditary cancer risk is now available and has the potential to reduce cancer mortality through the targeting of preventive therapies and by motivating behavioural change. However, generating and communicating genetic information can have psychological and social...

  • Variability in the use of CE-marked assays for in vitro diagnostics of CFTR gene mutations in European genetic testing laboratories. Camajova, Jana; Berwouts, Sarah; Matthijs, Gert; Macek, Milan; Dequeker, Elisabeth // European Journal of Human Genetics;Apr2009, Vol. 17 Issue 4, p537 

    DNA diagnostics of genetic diseases increasingly shifts towards utilization of commercial assays. Cystic fibrosis (CF)-related DNA diagnostics were used as a model for a pilot survey of the variability in the utilization of qualitative CE-marked in vitro diagnostic (IVD) assays and the scale of...

  • Distinctive audiometric profile associated with DFNB21 alleles of TECTA. Naz, S.; Alasti, F.; Mowjoodi, A.; Riazuddin, S.; Sanati, M.H.; Friedman, T.B.; A.J. Griffith; Wilcox, E.R. // Journal of Medical Genetics;May2003, Vol. 40 Issue 5, p360 

    Reports two novel mutations of the gene encoding alpha-tectorin (TECTA), predicted to be functional null alleles, which cosegregate with recessive, moderate to severe hearing loss in large consanguineous families. Distinctive phenotype associated with DFNB21 deafness as a clinical marker to...

  • Comprehensive genetics clinic for familial tumors: proposal for a suitable system in Japan. Fukushima, Yoshimitsu; Sakurai, Akihiro // International Journal of Clinical Oncology;Aug2004, Vol. 9 Issue 4, p304 

    With the progress of the Human Genome Project, genetic testing has become widely available and useful in several kinds of familial cancer. As the results of the genetic testing may predict future onset of the disease and/or may influence other family members, clinical oncologists have to...

  • Is BRCA 1/2 genetic testing cost effective in the USA?  // PharmacoEconomics & Outcomes News;1/21/2012, Issue 645, p6 

    The article reports on the findings by researchers from the University of Rochester School of Medicine that BRCA 1/2 genetic testing of women at high risk of carrying the BRCS 1 or 2 gene mutations, and treatment of those who test positive, seems to be cost effective compared with no genetic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics